Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 2/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 3/20 | 0.45 |
| ▸ | NEK2 | P51955 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.43 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.43 |
| ▸ | CDC7 | O00311 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | PRKACA | P17612 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7110570 | 0.88 | POLB (0.55) | KDREGFRNPC1POLBCDK5 | |
| SCHEMBL2996501 | 0.82 | AURKA (0.46) | KDREGFRPOLBMAP4K4PIM1 | |
| SCHEMBL4846337 | 0.82 | TTBK1 (0.43) | MKNK1SRCJAK2 | |
| SCHEMBL4899889 | 0.82 | EGFR (0.52) | KDREGFRNPC1POLBCDK2 | |
| SCHEMBL1590959 | 0.80 | GRM5 (0.49) | EGFRSRCNPC1 | |
| SCHEMBL5840442 | 0.80 | MKNK1 (0.47) | MKNK1EGFRAURKA | |
| SCHEMBL3001378 | 0.79 | NFKB1 (0.46) | EGFR | |
| SCHEMBL4899237 | 0.79 | CDK5 (0.37) | NPC1POLBCDK5CDK5R1CDK2 | |
| SCHEMBL22411720 | 0.78 | CCNA2 (0.50) | CDK5CDK5R1CDK2CLK4 | |
| SCHEMBL4894146 | 0.78 | HPGD (0.60) | NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090849-A1 | NOVEL PURINE DERIVATIVES, PREPARATION METHOD AND USE AS MEDICINES | AVENTIS PHARMA S.A. (FR) | 2008-04-17 | — | — | US | disclosed |
| US-7041824-B2 | Purine derivatives, preparation method and use as medicines | AVENTIS PHARMA S.A. (FR) | 2006-05-09 | — | — | US | disclosed |
| US-20060074095-A1 | Novel purine derivatives, preparation method and use as medicines | AVENTIS PHARMA S.A. (FR) | 2006-04-06 | — | — | US | disclosed |
| US-20040063732-A1 | Novel purine derivatives, preparation method and use as medicines | AVENTIS PHARMA S.A. (FR) | 2004-04-01 | — | — | US | disclosed |
| EP-1347975-A1 | NOVEL PURINE DERIVATIVES, PREPARATION METHOD AND USE AS MEDICINES | Aventis Pharma S.A. (FR) | 2003-10-01 | — | — | EP | disclosed |
| WO-2002051843-A1 | NOVEL PURINE DERIVATIVES, PREPARATION METHOD AND USE AS MEDICINES | AVENTIS PHARMA S.A. (FR) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063732-A1 | Novel purine derivatives, preparation method and use as medicines | CDK1, CDK6, PNP | MKNK1 431/4885KDR 4101/4885EGFR 4362/4885 |
| US-20080090849-A1 | NOVEL PURINE DERIVATIVES, PREPARATION METHOD AND USE AS MEDICINES | CDK1, CDK6, PNP | MKNK1 371/4885KDR 3412/4885EGFR 4061/4885 |
| US-20060074095-A1 | Novel purine derivatives, preparation method and use as medicines | CDK1, CDK6, PNP | MKNK1 426/4885KDR 3995/4885EGFR 4239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.